Advertisement
News
Advertisement

Tesaro buys rights to Amgen lung cancer tech program

Tue, 03/22/2011 - 7:33am
Mass High Tech: The Journal of New England Technology

Boston cancer-focused biotech startup Tesaro Inc. has landed an exclusive licensing deal with Amgen Inc., in which the Boston company will hold rights to Amgen’s Anaplastic Lymphoma Kinase (ALK) technology.

Tesaro intends to apply Amgen’s ALK tech to develop treatments for non-small cell lung cancer marked by ALK-positive tumors. ALK, expressed abnormally, may also be linked to lymphoma and neuroblastoma.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading